During the 1990–2000 decade, several attempts at mRNA-based anti-cancer vaccine development were made on a preclinical level, using induced expression of established cancer antigens such as carcinoembryonic antigen (CEA) and glycoprotein 100 (gp100). Here, PMEL is linked to cancer.